



GLOBAL JOURNAL OF MEDICAL RESEARCH: C  
MICROBIOLOGY AND PATHOLOGY  
Volume 17 Issue 1 Version 1.0 Year 2017  
Type: Double Blind Peer Reviewed International Research Journal  
Publisher: Global Journals Inc. (USA)  
Online ISSN: 2249-4618 & Print ISSN: 0975-5888

## Clinico-Hematological Study of Pancytopenia with Special Reference to Idiopathic Pancytopenia

By Hema Goyal, Dr. Vijai Tilak & Dr. Ankush Singhal

*Institute of Medical Sciences, Banaras Hindu University*

**Abstract- Background:** Pancytopenia may present with different clinical scenario in daily practice. The present study was carried out to find the various causes of pancytopenia in Varanasi and adjoining areas with special reference to Idiopathic pancytopenia.

**Material & Method:** It was a prospective study conducted over a period of one year (Jan 2014-February 2015) at Department of Pathology in Institute of Medical sciences, Banaras Hindu University, Varanasi. Patients presenting with pancytopenia were included in the study. A provisional diagnosis was made on the clinical findings. Extensive laboratory work up (including LFT, RFT, Serology etc) was carried out to find the cause of pancytopenia in all the patients. Bone marrow aspiration was done in all the cases as a routine procedure. Bone marrow biopsy was done in 48 cases where indicated.

**Keywords:** pancytopenia, aplastic anemia, myelodysplastic syndrome(MDS), idiopathic pancytopenia, idiopathic cytopenia of undetermined significance(ICUS).

**GJMR-C Classification:** NLMC Code: QV 180



*Strictly as per the compliance and regulations of:*



# Clinico-Hematological Study of Pancytopenia with Special Reference to Idiopathic Pancytopenia

Hema Goyal <sup>α</sup>, Dr. Vijai Tilak <sup>σ</sup> & Dr. Ankush Singhal <sup>ρ</sup>

**Abstract- Background:** Pancytopenia may present with different clinical scenario in daily practice. The present study was carried out to find the various causes of pancytopenia in Varanasi and adjoining areas with special reference to Idiopathic pancytopenia.

**Material & Method:** It was a prospective study conducted over a period of one year (Jan 2014-February 2015) at Department of Pathology in Institute of Medical sciences, Banaras Hindu University, Varanasi. Patients presenting with pancytopenia were included in the study. A provisional diagnosis was made on the clinical findings. Extensive laboratory work up (including LFT, RFT, Serology etc) was carried out to find the cause of pancytopenia in all the patients. Bone marrow aspiration was done in all the cases as a routine procedure. Bone marrow biopsy was done in 48 cases where indicated.

**Result:** A total of 140 patients presented with pancytopenia. Among the causes, Aplastic anemia was the most common cause (31.4%) followed by Megaloblastic anemia (22.1%) The third common cause was Myelodysplastic syndrome (MDS) (12.9%) followed by Acute leukemia (11.4%). Other causes were hypersplenism (4.3%), kala azar (2.1%), drug induced (2.1%), two cases each of HIV (1.4%), myelofibrosis (1.4%), lymphoma (1.4%) & multiple myeloma (1.4%). One case each of ITP (0.7%), SLE (0.7%) and Fanconi anemia (0.7%). Idiopathic pancytopenia constituted 5% (7 cases) of the total. On follow up of patients with idiopathic pancytopenia at 6 months, all the seven patients were having persistent pancytopenia. They were labeled as ICUS (Idiopathic cytopenia of undetermined significance (ICUS)). One patient was hospitalized with complains of generalized body weakness and few episodes of malena. Thorough work up was done to look for any cause of pancytopenia but no cause was identified and patient died due to complication of pancytopenia (due to hemorrhagic shock) in one month course and hence "Idiopathic fatal pancytopenia" term was coined for the patient. Remaining six patients were followed up at 12 months, 03 patients were having persisting pancytopenia without any specific complaints and remaining 03 patients died, for which cause is unknown.

**Conclusion:** Pancytopenia is a common haematological problem encountered in clinical practice. The natural history of patients with ICUS is largely unknown and appears to be highly variable. ICUS patients require long term follow up to assess the evolution. "Idiopathic fatal pancytopenia (IFP)" is an emerging new entity with a grave prognosis. Further research may elucidate the underlying pathology & potential drugs to halt the inevitable fatal outcome.

**Author α σ ρ:** Institute of Medical Sciences, Banaras Hindu University.  
e-mails: hemagoyal88@gmail.com, vijaitalak@rediffmail.com, singankush@gmail.com

**Keywords:** pancytopenia, aplastic anemia, myelodysplastic syndrome (MDS), idiopathic pancytopenia, idiopathic cytopenia of undetermined significance (ICUS).

## I. INTRODUCTION

Pancytopenia is the simultaneous occurrence of anemia, leucopenia and thrombocytopenia. Many disease processes involve the bone marrow primarily or secondarily resulting in pancytopenia. Pancytopenia can develop due to decrease in hematopoietic cell production as a result of destruction of marrow tissue by toxins, suppression of normal marrow growth and differentiation or due to replacement of bone marrow by abnormal or malignant tissue. The marrow may be hypocellular or hypercellular. Bone marrow examination usually provides the diagnosis in these cases. Few cases where exact diagnosis could not be made even after an exhaustive work up, these cases were regarded as Idiopathic pancytopenia. We followed up these cases at 6 month and 12 month. We particularly emphasized on these cases with the comparative study with other diagnosis. No study undertaken in this regard in India yet.

## II. MATERIAL AND METHOD

The present study was a prospective study. A total of 140 patients presenting with pancytopenia were enrolled in the study. Approval from Ethical Committee and patient consent were taken. These 140 patients were divided into two age groups : Children (<18 years) & Adult (≥18 years). The inclusion criteria for pancytopenia were hemoglobin (Hb) less than 10 gm/dL, total leukocyte count (TLC) less than 4000/cumm and platelet count less than 150000/cumm. A detailed clinical history and physical examination was undertaken in all the cases. A provisional diagnosis was made on these clinical findings. Peripheral smear examination and reticulocyte count was done. Samples of bone marrow aspiration were taken from the patients admitted in the Department of Medicine and Pediatrics of Sir Sunderlal Hospital, Banaras Hindu University, Varanasi. All the patients were checked for having any major clotting disorder before undergoing any procedure. BMA was performed by the standard

technique using Salah needle from the posterior iliac crest under local anesthesia with standard aseptic precautions. Leishman stain was used to stain all bone marrow smears. BM aspirate for cytogenetics was taken into a sodium heparin tube. Excess aspirate was used to make particle clot preparations or placed in an EDTA tube for making additional smears. Special cytochemical stains were undertaken in cases of

leukemia. rk-39 dipstick test was done in all cases of Kala-azar. Bone marrow biopsy was done in 48 cases where the diagnosis was doubtful on aspiration. Chromosomal breakage study was advised in a suspected case of Fanconi anemia. Immunohistochemistry (IHC) with CD34 was done on biopsy section in certain cases to enumerate the exact count of blast. We followed the algorithm presented in figure 1.

#### Algorithm for Work Up of Cases of Pancytopenia




Figure 1: Algorithm for work up of cases of pancytopenia

### III. RESULTS

A total of 140 patients of pancytopenia were enrolled in the study. The patient age ranged from 1 to 72 years. The maximum number of patients of pancytopenia were found in 11-20yr age group, followed by age group 21-30years. The overall male to female ratio (M:F) was 1.37:1. Out of 140 patients, 92 patients (66%) were adults and 48 (34%) were children.

The most common cause of pancytopenia in our study was Aplastic anemia in 44 cases (31.4%) followed by Megaloblastic anemia in 31 cases (22.1%). The incidence of Idiopathic pancytopenia in our study was 5%. Incidence of various causes of pancytopenia are tabulated in table 1.

**Table 1:** Incidence of various causes of pancytopenia (n=140)

Diagnosis	Number of cases	Incidence (%)
Aplastic anemia	44	31.4
Megaloblastic anemia	31	22.1
o without IDA	18	
o with IDA	13	
Myelodysplastic syndrome (MDS)	18	12.9
Acute leukemia	16	11.4
Hypersplenism	6	4.3
Kala-azar	3	2.1
HIV	2	1.4
Septicemia	1	0.7
Drug induced	3	2.1
Lymphoma	2	1.4
Myelofibrosis	2	1.4
Multiple myeloma	2	1.4
Fanconi anemia	1	0.7
SLE	1	0.7
ITP(Immune thrombocytopenia purpura)	1	0.7
<b>IDIOPATHIC (?Cause)</b>	<b>7</b>	<b>5</b>
<b>TOTAL</b>	<b>140</b>	<b>100%</b>

**Table 2:** Profile of Idiopathic pancytopenia (n=07) cases.

Case no	Age	Sex	Hb(gm%)	TLC(/ul)	Platelet(/cumm)	MCV(fl)	%Blast in PBS*	%blast in BM	BM** cellularity	BM fibrosis	CD34on BM cells	Cytogenetics
1	60	M	4.3	1100	13000	72	0	0	NC***	No	0	46,XY
2	17	F	4.9	3100	39000	84.1	0	0	NC	No	0	46,XX
3	65	M	4.5	2200	11000	106	0	0	NC	No	0	46,XY
4	11	M	10.6	2700	84000	90	0	0	NC	No	0	46,XY
5	17	M	4.4	2600	75000	90	0	0	NC	No	0	46,XY
6	55	M	9.5	3700	29000	86.2	0	0	NC	No	0	46,XY
7	38	M	7.4	3800	23000	100	0	0	NC	No	0	46,XY

\*PBS – peripheral blood smear, \*\*BM- bone marrow, \*\*\*NC- normocellular

The mean age of patients of Idiopathic pancytopenia was  $37.6 \pm 22.7$  years. There were 3 children and 4 adults. The male to female ratio was 6:1. The mean Hb (gm/dl) was  $6.5 \pm 2.6$  (4.3-10.6), mean TLC(/cumm) was  $2743 \pm 929$  (1100-3800), mean Platelet count (/cumm) was  $39100 \pm 29260$  (11000-86000) and mean MCV (fl) was  $89.7 \pm 11$  (72-106).

In our study, 7 cases presented with pancytopenia with normocellular marrow. No signs of

dysplasia or increase in blast count were noted. Bone marrow biopsy was undertaken for these patients. No bone marrow fibrosis was noted. No CD34 positive cells (blast) were seen in the bone marrow by IHC. Conventional cytogenetics was performed on bone marrow aspirate and it was normal in all the cases. These cases did not respond to Vitamin B12 and folic acid therapy. Serum biochemical parameters and coagulation profile was within normal limit.

Autoimmune profile was conducted for these patients and was within normal limit. Radiological investigations were done to rule out any specific pathology. On follow up at 6 months all seven cases were having persistent pancytopenia. These cases were diagnosed as ICUS (idiopathic cytopenia of undetermined significance). One patient presented with generalized body weakness and few episode of malena in the past. The patient was hospitalized and further work up was started to find the cause of

malena and pancytopenia. In due course, patient had declining trend in the hematological parameters and started bleeding and went into hemorrhagic shock and died. No cause of pancytopenia could be identified and hence we coined the term Idiopathic fatal pancytopenia for this patient. Remaining six patients were followed up at 12 months, 3 patients were having persistent pancytopenia and three patients died, for those the cause is not known as they were not available for any work up.

**Table 3:** Table showing frequency of various symptoms and signs.

Symptoms & signs	Number of patients (out of 140)	Percentage %
Generalized body weakness	126	90
Pallor	137	97.8
Fever	86	61.4
Bleeding	57	40.7
Splenomegaly	26	18.6
Hepatomegaly	16	11.4
Lymph node	15	10.7
Pedal edema	10	7.14

The most common presenting symptom was generalized body weakness in 126 patients (90%). The most common sign was pallor in 137 cases (97.8%)

The various causes of pancytopenia were divided into five categories for further evaluation as Aplastic anemia, Megaloblastic anemia, Infiltrative disorders [including acute leukemia-myeloid (AML) and

lymphoid (ALL), myelodysplastic syndrome (MDS), lymphoma, multiple myeloma], Others [including, Fanconi anemia, hypersplenism, kala-azar, HIV, septicemia, drug induced causes, SLE, myelofibrosis and immune mediated thrombocytopenic purpura (ITP)] and Unknown causes (idiopathic pancytopenia)

**Table 4:** Table showing relationship of MCV, RDW-CV, & MPV with different causes of pancytopenia.

Diagnosis	MCV(fl) Chi square (DF=8) 55.78 P value <0.05			RDW-CV (%) Chi square (DF=4) 31.26 P value <0.05		MPV(fl) Chi square (DF=4) 88.04 P value <0.05	
	< 83fl	83-99fl	>99fl	11.6-14%	>14%	6-13fl	>13fl
Aplastic anemia	3	34	7	31	13	44	0
Megaloblastic anemia	4	3	24	2	29	6	25
Infiltrative disorders	7	22	9	14	24	36	2
Others	8	11	1	8	12	18	2
Unknown cause	1	4	2	3	4	7	0
Number of cases	23	74	43	58	82	111	29

In our study, MCV was significantly increased in cases of pancytopenia due to megaloblastic anemia (24 out of 31 cases) where as it was within normal range in other causes of pancytopenia due to aplastic anemia and infiltrative causes. The correlation between megaloblastic anemia and macrocytic anemia was found to be significant in our study with p value <0.05. Aplastic anemia and other infiltrative conditions were associated with normocytic anemia which was found to be significant. Red cell distribution width RDW-CV was significantly increased in cases of pancytopenia due to megaloblastic anemia as compared to other causes which had normal RDW values. Mean platelet volume (MPV) was also significantly increased in cases of

megaloblastic anemia as compared to other causes of pancytopenia (aplastic anemia, infiltrative lesion).

#### IV. DISCUSSION

Pancytopenia is defined by reduction of all the three formed elements of blood below the normal reference range<sup>[1]</sup>. Pancytopenia is a common hematological finding with different clinical scenario.

In our study the male: female ratio was 1.37:1. This is in agreement with other studies shown in (table 5). The male preponderance may be partly explained by increased exposure of male to environmental agents like agricultural pesticide<sup>[2]</sup>. Few studies showed female preponderance<sup>[3,4]</sup>. The most common symptom was generalized body weakness (90%) and most



common sign was pallor (97.8%) comparable to many other Indian studies (table 5).

We compared our data with various International and Indian studies on pancytopenia (table 6). The most common cause in our study was Aplastic anemia. Many International studies<sup>[5,6,7,8,9,10,11,12]</sup> and national studies<sup>[4,13,14]</sup> were in agreement with our finding as aplastic anemia as the most common cause of pancytopenia. Whereas few studies reported aplastic anemia as the second most common cause<sup>[15,16,17,18,19,20,22]</sup>. Significant lymphocytosis was associated with aplastic anemia compared to other causes of pancytopenia. This finding was in agreement with SomaYadav *et al.*, The pathophysiology of Aplastic anemia is believed to be immune mediated, with active destruction of blood forming cells by the lymphocytes<sup>[4]</sup>.

Megaloblastic anemia was the 2<sup>nd</sup> common cause in our study whereas few Indian studies<sup>[18,19,20,21, 22, 23,24,25]</sup> and international studies<sup>[16,34]</sup> reported it as the first common cause. This may be due to the fact that ours is a tertiary care centre where many referral cases come which might have been treated with hematinic therapy previously.

Out of 31 cases of Megaloblastic anemia, 26 had elevated LDH levels. All the cases improved with Vitamin B12 and folic acid therapy. R Para *et al.*, and Evazi-ziaei *et al.*, also observed increased LDH in megaloblastic anemia<sup>[25,26]</sup>. Lactate dehydrogenase enzymes is released during the The expected increase in LDH activity is the result of an accelerated turnover of bone marrow cells implying release of this enzyme from dividing or decaying cells.<sup>[27]</sup>

In MDS, most of the patients (75%) were under the age 50years and 27% of cases were below 20 years. Usually MDS is considered to be disease of elderly, but in the Indian series by S Nigam and Sudha Rani *et al.*, overall 75.5% of individual (20/33) were of <50 years of age, 8 (21.6%) of 33 patients were less than 20 years of age<sup>[28]</sup>. This may be due to the fact that the incidence of MDS appears to be increasing over the past decade due to recognition of the syndrome by the physician and hematopathologist.

Acute leukemia is the 3<sup>rd</sup> common cause in our study. Many Indian studies are in agreement with ours study. Sarod R *et al.*, reported acute leukemia as the 2<sup>nd</sup> common cause.<sup>[29]</sup>

Various International studies reported few cases of pancytopenia with normal bone marrow (refer table 6). The frequency varies from 3.38% to 10.5%. No follow up was mentioned in them. No study has reported the phenomenon of Idiopathic pancytopenia. In our study we reported 5% of these cases (pancytopenia with normal marrow and normal karyotype). We followed up these cases at 6 months and 12 months.

ICUS is a recently proposed, provisional diagnostic category that recognizes patients who

present with cytopenias of undetermined etiology<sup>[30,31]</sup>. The proposed criteria for diagnosing ICUS<sup>[30]</sup>:

- Persistent cytopenia (for 6 months): hemoglobin <11 g/dl, neutrophils <1.5×10<sup>9</sup>/L, and platelets <100×10<sup>9</sup>/L;
- No morphologic features of myelodysplasia
- Normal chromosome analysis and
- A detailed clinical history and investigation that excludes other secondary causes of cytopenias.

The natural history of patients with ICUS is largely unknown and appears to be highly variable<sup>[32]</sup>. Small studies indicate that some patients will go on to develop frank MDS or a related myeloid malignancy such as AML<sup>[33]</sup>. Others may follow a more indolent course<sup>[34]</sup>. ICUS cases require long term follow up to assess the evolution. In our study, all the seven cases fulfilled the criteria for ICUS. One patient was hospitalized for an extensive work up but within one month patient died due to hemorrhagic shock and no cause could be identified. The course of the patient was fatal and hence the patient was termed as Idiopathic fatal pancytopenia. Out of remaining six patients on follow up at 12 months, three patients were having persistent pancytopenia and another three patients were expired due to unknown cause. Hence the course of ICUS in our study was variable.

The incidence of hypersplenism was 4.3%. All cases were caused by portal hypertension secondary to liver cirrhosis. The incidence of pancytopenia caused by hypersplenism among international studies varied from 0 % to 19%<sup>[14,29]</sup> as well as among Indian studies varied from 0 %-11.5%. Our incidence of 4.3% was within the range reported by various workers.

Other infections included Septicemia and HIV. The incidence was 2.1% in our study. There was a single case of septicemia presenting as pancytopenia in children. Two cases of HIV in adults were reported. The incidence of septicemia in various studies varied from 1.6% to 17.2%<sup>[4,19,25,35]</sup> and our data was within the aforementioned range.

There was a single case of ITP in a 17 year old female with fever, pallor and petechial rashes. The incidence of ITP in our study was 0.7%. In other studies, the incidence varied from 1.7-7.8%.<sup>[23,25,13]</sup>

We also compared our data with various studies in children (table 7). Overall in adult(51.1%) and children (58.4%), aplastic anemia and megaloblastic anemia were the two most common causes of pancytopenia in our study.

MCV, RDW-CV & MPV was significantly increased in cases of pancytopenia due to megaloblastic anemia where as it was within normal range in other causes of pancytopenia due to aplastic anemia and infiltrative causes. Soma Yadav *et al.*, & Gupta *et al.*, also assessed the role of MCV, RDW, MPV in

cases of pancytopenia and they are in agreement with our study.<sup>[4,38]</sup>

## V. CONCLUSION

Pancytopenia is a common hematological problem encountered in clinical practice. The most common cause of pancytopenia is Aplastic anemia followed by Megaloblastic anemia. ICUS cases require long term follow up. "Idiopathic fatal pancytopenia (IFP)" is an emerging new entity with a grave prognosis. We wish to sensitize the medical community & the scientists to this rapidly fatal condition of unknown etiology. Further research may elucidate the underlying pathology & potential drugs to halt the inevitable fatal outcome.

## REFERENCES RÉFÉRENCES REFERENCIAS

- Williams DM. Pancytopenia, Aplastic anemia and Pure Red cell aplasia In: Wintrobe's Clinical Hematology (10th edition). Baltimore: William and Wilkins; 1993.1449-1484
- Meittinen OS. Proportion of disease caused or prevented by a given exposure, trait or intervention. *Am J Epidemiol* 1974; 99: 325.
- Kumar DB, Raghupathi AR. Clinicohematologic analysis of pancytopenia study in a tertiary care centre. *Basic and Applied Pathology* 2012; 5: 19–21
- Yadav S, Kushwaha R, Aggrawal K, Tripathi AK, Singh US, Kumar AK. A Clinico- hematological study in cases of pancytopenia: correlation of automated cell counter parameters in various etiologies. *Journal of Evolution of Medical and Dental Sciences*.2013, Volume 2(22): Page 4013-4023.
- International agranulocytosis and aplastic anaemia study. Incidence of aplastic anaemia: the relevance of diagnostic criteria. *Blood* 1987; 70: 1718-1721.
- Hossain MA, Akond AK, Chowdhary MK. Pancytopenia – A study of 50 cases. *Bangladesh Journal of Pathology* 1992; 1: 9-12.
- Niazi. M, Raziq F: The incidence of underlying pathology in pancytopenia. *Journal of postgraduate medical institute (JPMI)* 2004: 76-9.
- Jha A, Sayami G, Adhikari RC, Patna AD, Jha R. Bone marrow examination in cases of pancytopenia. *J Nepal Med Assoc* 2008;47:12-7.
- Lakhey A, Talwar OP, Singh VK, KC SR. Clinico-hematological study of pancytopenia. *Journal of Pathology of Nepal*. 2012;2;207–10.
- Khan TA, Khan IA, Mahmood K. Clinicohaematological spectrum of pancytopenia in a tertiary care hospital. *J Postgrad Med Inst* 2013; 27(2): 143-7.
- Jan AZ, Zahid B, Ahmad S, Gul Z. Pancytopenia in children: A 6-year spectrum of patients admitted to Pediatric Department of Rehman Medical Institute, Peshawar. *Pak J Med Sci* 2013; 29(5): 1153-1157.
- Pathak R, Jha A, Sayami G. Evaluation of bone marrow in patients with pancytopenia. *Journal of Pathology of Nepal*. 2012; 2: 265–71.
- Varma N and Dash. S: Reappraisal of underlying pathology in adult patients presenting with pancytopenia. *Trop Geogr Med* 1992; 44: 322-327.
- Kumar R, Kalra SP, Kumar H, Anand AC, Madan H. Pancytopenia - a six year study. *J Assoc PhysIndia* 2001; 49: 1078-81.
- Keisu M and Ost A. Diagnosis in patients with severe pancytopenia suspected with severe aplastic anaemia. *Eur J Haematol* 1990; 45: 11-14
- Savage DG, Allen RH, Gangaidzo IT *et al*. Pancytopenia in Zimbabwe. *Am J Med Sci* 1999; 317: 22–32
- Abbas K, Al-Zubaidy AS, Rhaima M; Pancytopenia adult patients at baghdad teaching hospital, The Iraqi Postgraduate Medical Journal; 2011,10(4): 441-8.
- Tilak V, Jain R. Pancytopenia-A Clinico-hematologic analysis of 77cases. *Indian J Pathol Microbiol*. 1992; 42: 399–404
- Khodke K, Marwah S, Buxi G, Vadav RB, Chaturvedi NK. Bone marrow examination in cases of pancytopenia. *J Academy Clin Med*. 2001; 2: 55–9.
- Khunger JM, Arculsevi S, Sharma U, Ranga S, Talib VH. Pancytopenia-A Clinico-hematological study of 200 cases. *Indian J Pathol Microbiol*.2002;45:375–9.
- Parmar JK , Sheikh S, Vidja P, Etiological evaluation of Pancytopenia with special emphasis on megaloblastic anemia, *Paripex, Indian journal of research*. 2013; Vol 3(4); p263-264
- Nigam RK, Chaudhary R, Malik R, Gour D, Shrivastava A, Tripathi A, Ahirwar R, Jain R. "Pancytopenia- clinico-haematological studies of bone marrow examination". *Journal of Evolution of Medical and Dental Sciences* 2013; Vol. 2(7), Page: 9213-9219.
- Thakkar B B, Bhavsar N Ukti, Trivedi N J, Agnihotri AS. A study of pancytopenia in adult patients more than 12 years of age in north west region of saurashtra. *National Journal of medical research*. 2013; 3(1); 48-52
- Chhabra A, Chandar V, Patel A, Chandra H. Clinico-aetiological profile of pancytopenia in paediatric practice *Journal, Indian Academy of Clinical Medicine*, 2012,13(4 I); 282-5.
- Para R, Para S. Pancytopenia - a study of 58 cases. *Journal of Evolution of Medical and Dental Sciences* 2013; Vol. 2(45); 8724-8728
- Eivazi-ziaei J, Dastgiri S, Sanaat Z. Estimation of the Diagnostic Value of Myeloperoxidase Index and Lactate Dehydrogenase in Megaloblastic Anaemia. *Journal of Clinical and Diagnostic Research*. 2007; 1(5):380-384
- Cucuianu A, Trif I, Cucuianu M, et al. Serum lactate dehydrogenase and alkaline phosphatase activities

- and serum cholesterol level in bone marrow blood. Rom J Intern Med 1996; 34(3-4): 173-82.
28. Nigam S, Rani S, Sing T *et al.*, Clinical, Haematological and Histomorphological Profile of Myelodysplastic Syndrome. JAPI 2001; 49:430-434
  29. Sarode R, Garewal G, Marwaha N *et al.* Pancytopenia in nutritional megaloblastic anemia. A study from north-west India. Trop Geogr Med 1989; 41: 331-6
  30. Valent P, Horny H-P, Bennett JM, Fonatsch C, Germing U, Greenberg P *et al.* Definitions and standards in the diagnosis and treatment of the myelodysplastic syndromes: Consensus statements and report from a working conference Leukemia Research, 2007(31); 727-736
  31. Valent P, Bain BJ, Bennett JM, Wimala F, Sperr WR, Mufti G, Horny HP, Idiopathic cytopenia of undetermined significance (ICUS) and idiopathic dysplasia of uncertain significance (IDUS), and their distinction from low risk MDS, Leukemia Research, 2012(36); 1-5
  32. Kwok B, Hall JM, Witte J S, Xu Y, Reddy P, Lin K, Flamholz R, Dabbas B, Yung A, Al-Hafidh J, Balmert E, Vaupel C, Hader C E, McGinniss MJ, Nahas S A, Kines J, Bejar R : MDS-associated somatic mutations and clonal hematopoiesis are common in idiopathic cytopenias of undetermined significance; BLOOD, 2015; VOL. 126(21); 2355-61
  33. Schroeder T, Ruf L, Bernhardt A, Hildebrandt B, Aivado M, Aul C *et al.* Distinguishing myelodysplastic syndrome (MDS) from idiopathic cytopenia of undetermined significance (ICUS): HUMARA unravels clonality in a subgroup of patients. Ann Oncol. 2010; 21(11): 2267-2271.
  34. Busque L, Patel JP, Figueroa ME, *et al.* Recurrent somatic TET2 mutations in normal elderly individuals with clonal hematopoiesis. Nat Genet. 2012; 44(11): 1179-1181.
  35. Devi PM, Laishram R S, Sharma P S, Singh A M, Singh M K, Singh Y M. Clinico-hematological Profile of Pancytopenia in Manipur, India. Kuwait Medical Journal. 2008, 40 (3): 221-224.
  36. Gupta V, Tripathi S, Tilak V, Bhatia BD. A study of clinico-hematological profiles of pancytopenia in children; Tropical Doctor ;October 2008;38;241-243
  37. Imbert M, Scoazec JY, Mary JY, Jouzult H, Rochant H, Sultan C. Adult patients presenting with pancytopenia: a reappraisal of underlying pathology and diagnostic procedures in 213 cases. Hematol Pathol. 1989; 3(4): 159-67.
  38. Gupta PK, Saxena R, Karan AS, Choudhary VP. Red cell indices for distinguishing macrocytosis of aplastic anemia and megaloblastic anemia. Indian J Pathol Microbiol 2003;46(3):375-377
  39. Jain A, Naniwadekar M: An etiological reappraisal of pancytopenia - largest series reported to date from a single tertiary care teaching hospital. BMC Hematology 2013 13:10
  40. Ishtiaq O, Baqai H Z, Anwer F, Hussain N: Patterns of pancytopenia patients in a general medical ward and a proposed diagnostic approach. J Ayub Med Coll Abbottabad; 2004; 1: 8-13
  41. Pudasaini S, Prasad KBR, Rauniyar SK, Shrestha R, Gautam K, Pathak R, Koirala S, Manandhar U, Shrestha B. "Interpretation of bone marrow aspiration in hematological disorder". J of Pathology of Nepal 2012; 2: 309-312.

**Table 5:** Comparison of clinical profile of pancytopenia patients.

Study	Age group	M:F ratio	Most common presentation	Most common sign
Deepak B. Kr <i>et al.</i> , 3	10-70yr	1.0:1.8	Generalised weakness (70.83%)	Pallor (45.83%)
Soma Yadav <i>et al.</i> , 4	All ages, <30yr- 73.3%	1:1.2	Fever	Pallor
Jignesh Kumar <i>et al.</i> , 21	1-95yr	1.6:1	Easy fatigability (79%)	Pallor (100%)
Nigam RK <i>et al.</i> , 22	2-80yr	1.12:1	Generalized weakness, fever	Pallor, splenomegaly
Bhaskar B Thakkar <i>et al.</i> , 23	13-86yr	1.08:1	Generalised weakness (97%) and fever (70%)	Pallor (100%)
A Chhabra <i>et al.</i> , 24	6month – 14yr	-	Bleeding manifestation (70.3%) Fever (63.7%)	Pallor (64.8%)
Rajesh Para & Shailajapara <i>et al.</i> , 25	3-90 yr	1.1:1	Generalized weakness (51.7%)	Pallor (25.9%)
Arvind Jain <i>et al.</i> , 39	2month-95yr	2.6:1	-	-
Present study	1-72yr	1.37:1	Generalised weakness (90%)	Pallor (97.8%)



Table 6: International &amp; National Studies on Pancytopenia.

Study	Country	No. of cases	Commonest cause of pancytopenia	Second common cause	Third common
International agranulocytosis and aplastic anemia study 5	Israel Europe 1987	389	Aplastic anemia (52.7%)	MDS (10.5%)	-
Keisu M and Ost A <i>et al.</i> , 15	Israel Europe 1990	100	Neoplastic disease, Radiation therapy (32%)	Aplastic anemia (19%)	MDS (14%)
Hossain MA <i>et al.</i> , 6	Bangladesh 1992	50	Aplastic anemia	Chronic malaria, Kala-azar	Hypersplenism, Acute leukemia
David G, Savage 16	Zimbabwe 1997	134	Megaloblastic anemia 48 (35.8%)	Aplastic anemia 35 (26.1%)	AIDS, Acute leukemia (11.82%)
Mussarrat Niazi Fazl-i-Razig 7	Pakistan 2000	89	Aplastic anemia (38.3%)	Megaloblastic anemia (24.7%)	-
Ishtiaq O Bagai HZ40	Pakistan 2001	100	Megaloblastic anemia 39 (39%)	Hypersplenism secondary to cirrhosis 19 (19%)	-
Khudairabbas <i>et al.</i> , 17	Iraq 2004	105	Acute leukemia (30.47%)	Aplastic anemia (17.14%)	Non hodgkinslymphoma (14.47%), megaloblastic anemia (13.33%)
Jha <i>et al.</i> , 8	Nepal 2008	148	Hypoplastic anemia (29%)	Megaloblastic anemia (23.64%)	Hematological malignancies (21.62%), erythroid hyperplasia (19.6%) and <b>normal marrow in 3.38% cases</b>
Lakhey <i>et al.</i> , 9	Nepal 2010	54	Hypoplastic anemia (29.6%)	Hematological malignancies (27.78%)	Megaloblastic anemia (24.1%), erythroid hyperplasia (11.11%), <b>normocellular marrow in 7.41% cases</b>
Tajali khan <i>et al.</i> , 10	Pakistan 2011	160	Aplastic anemia (37.5%)	Megaloblastic anemia (13.75%)	Acute leukemia (13.75%), hypersplenism (10%)
Pudasaini <i>et al.</i> , 41	Nepal 2012	57	Erythroid hyperplasia (21%)	Megaloblastic anemia (12.3%)	Acute leukemia (12.3%), infective pathology (12.3%), ITP (10.5%), microcytic anemia (7%), hypoplastic anemia (5.3%), MDS (3.5%), Multiple myeloma (3.5%), leishmaniasis (1.8%) and <b>normal marrow in 10.5%</b>
Anwar jebjan <i>et al.</i> , 11	Pakistan 2012	205	Aplastic anemia (28.3%)	Hematological malignancies (23.9%)	Megaloblastic anemia (19.5%), ITP (7.8%), Iron deficiency anemia (4.4%)
Pathak <i>et al.</i> , 12	Nepal 2013	102	Hypoplastic anemia (32.3%)	Hematological malignancies (19%)	Megaloblastic anemia (11.7%), erythroid hyperplasia (20%), Leishmaniasis, plasmacytosis, gaucher diseases, relative myeloid hyperplasia, eosinophilia, <b>normocellular marrow in 5.8% cases and 5.8% cases remain inconclusive</b>
N Verma and S Dash 13	India 1992	202	Aplastic anemia (40.6%)	Megaloblastic anemia (23.26%)	Acute leukemia (17.75%)
Vijai Tilak, Raini Jain 18	India 1999	77	Megaloblastic anemia (68%)	Aplastic anemia (7.7%)	
Kumar R, Kalra SR 14	India 1997	166	Aplastic anemia- (29.5%)	Megaloblastic anemia (22.28%)	Aleukemic leukemia (12%)
Kishor Khodke and S. Marawah 19	India 1999	50	Megaloblastic anemia (44%)	Aplastic anemia (14%) and Kalazar (14%)	
Sarod R, Garewal 29	India 2001	139	Aplastic anemia 38%	Acute leukemia	
Khunger JM, S Arulselvi 20	India, 2002	200	Megaloblastic anemia (72%)	Aplastic anemia (14%)	Subleukaemic leukemia (5%)
Jignesh kumar <i>et al.</i> 21	India, 2011	100	Megaloblastic anemia (45%)	Malaria (14%)	Aplastic anemia (11%)
Nigam RK <i>et al.</i> , 22	India, 2012	155	Megaloblastic anemia (43.2%)	Hypoplastic anemia (12.9%)	Dimorphic anemia (8.38%), hypersplenism (3.22%), aplastic anemia (2.58%), ITP, MDS, chediak-higashi syndrome, CDA, PRCA, Erythroid hyperplasia, gaucher's

Deepak B.Kr etal <sup>3</sup>	India, 2012 (18month)	48	Hypoplastic anemia (33.3%)	Normoblasticerythroid hyperplasia (27.8%)	Megaloblasticanemia (18.75%), MDS (8.33%), Normal marrow and dry tap (12.5%)
Soma yadav <i>et al.</i> , <sup>4</sup>	India, 2012	60	Aplastic anemia (38.3%)	Megaloblasticanemia (21.7%)	Leukemia, non-Hodkings lymphoma, infiltration, MDS
Bhaskar b thakkar <i>et al.</i> , <sup>23</sup>	India, 2012	100	Megaloblasticanemia (37%)	Malaria(19%)	Hypersplenism (14%), and aplastic anemia (6%), TB (5%)
A chhabra <i>et al.</i> , <sup>24</sup>	India, 2012	111	Megaloblastic anemia (31.8%)	Hematological malignancies (25.2%)	Infectious diseases (19.7%) Aplastic anemia (18.8%)
Rajesh Para & Shailajapara <i>et al.</i> , <sup>25</sup>	India, 2013	58	Megaloblastic anemia (46.6%)	HIV(17.2%)	Malaria(8.6%), aplastic anemia (8.6%), dengue (8.6%), subleukemic leukemia (3.4%), ITP, Iron deficiency anemia
Arvindjain <i>et al.</i> , <sup>39</sup>	India, 2013	250	Hypersplenism (29.2%)	Infection (25.6%)	Myelosuppresants (16.8%) Megaloblastosis (13.2%)
Present Study	India 2014-2015	140	Aplastic anemia (31.4%)	Megaloblastic anemia (22.1%)	Myelodysplastic syndrome (12.9%), Acute leukemia (11.4%), Hypersplenism (4.3%), kala-azar (2.1%), other infection(2.1%), <b>normocellular marrow in 5% cases(IDIOPATHIC PANCYTOPENIA)</b>

Table 7: Comparison of Various Studies in Children

Study	Country	Number of cases	AGE	Most common cause	2 <sup>nd</sup> Most common cause	3 <sup>rd</sup> Most common cause
Gupta V <i>et al.</i> , <sup>36</sup>	India 2008	105	1.5-18yr	Aplastic anemia (43.8%)	Acute leukemia (25.7%)	Kala azar (9.5%)
Chabbara A <i>et al.</i> , <sup>24</sup>	India 2012	111	6 month - 14 yr	Megaloblastic anemia (31.8%)	Malignancies (25.2%)	Infectious diseases (19.7%)
Jan AZ <i>et al.</i> , <sup>11</sup>	Pakistan 2013	205	6 month- 14 year	Aplastic anemia (28.3%)	Hematological malignancies (25.2%)	Megaloblastic anemia (19.5%)
Pathak <i>et al.</i> , <sup>12</sup>	Nepal 2013	6(out of 48)	< 15yr	Hypoplastic anemia (3cases)	Hematological malignancies (2 cases)	Megaloblastic anemia (1 case)
Present Study	India 2015	48(out of 140)	< 18yr	Aplastic anemia (41.7%)	Megaloblastic anemia (16.7%)	Acute leukemia (12.5%) MDS (8.3%)